Johnson & Johnson closes acquisition of Conor Medsystems
02 Feb '07
1 min read
Johnson & Johnson announced the closing of its previously announced acquisition of Conor Medsystems Inc, a cardiovascular device company with a unique controlled drug delivery technology.
"The completion of the acquisition of Conor Medsystems adds an important platform to our capacity to address cardiovascular and vascular disease globally," said Nicholas J. Valeriani, Worldwide Chairman, Medical Devices and Diagnostics, Johnson & Johnson.
The Conor Medsystems CoStar Stent provides for drug elution from a cobalt chromium stent with a fully bioabsorbable polymer, and employs a unique site-specific drug delivery technology potentially applicable with other therapeutic agents in the treatment of other conditions.
"We look forward to exploring the potential for this novel reservoir technology in combination with other pharmaceutical agents and delivery systems as we seek new and better ways to address issues of cardiovascular and vascular disease," Valeriani concluded.
marketing@alchempro.com
